74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Omeros Corp
Closed
SectorHealthcare
7.34 -8.71
Overview
Share price change
24h
Min
6.9
Max
7.99
Income | 24M -32M |
|---|---|
EPS | -0.55 |
Employees | 198 |
EBITDA | -33M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +220.35% upside |
Market Cap | 275M 491M |
|---|---|
Previous open | 16.05 |
Previous close | 7.34 |
News Sentiment
By Acuity
30%
70%
94 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Omeros Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Omeros Corp Forecast
Price Target
By TipRanks
220.35% upside
12 Months Forecast
Average 25.66 USD 220.35%
High 45 USD
Low 6.33 USD
Based on 3 Wall Street analysts offering 12 month price targets forOmeros Corp - Dist in the last 3 months.
Sentiment
By Acuity
94 / 386 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Omeros Corp
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
